Merck Starts To Suspend Worldwide Availability Of Tredaptive

In the wake of the negative HPS2-THRIVE study announced last month, Merck said today that it was beginning to suspend the worldwide availability of Tredaptive, its combination of extended-release niacin and laropiprant.

Click here to read the full story on Forbes.

Leave a Reply

%d bloggers like this: